Malaysia equips 156 health clinics with AI-driven CCMS for faster care
Datuk Seri Dr Dzulkefly Ahmad revealed that 70 per cent of patients now receive treatment in under 30 minutes, marking a milestone in the ministry's AI-driven digital reforms.
The initiative is part of broader upgrades, including the completion of Phase 1 of the Electronic Medical Record (EMR) system. This phase covers five million prescriptions, 20 million vaccination records, and one million dental records.
Dzulkefly noted that MySejahtera has evolved into a preventive health gateway and national digital platform.
'We are exploring a strategic collaboration with Google to leverage AI in tackling Malaysia's key health challenges,' he said in a Facebook post. 'This positions Malaysia as a regional leader in AI-based digital health.'
As ASEAN Chair in 2025, Malaysia aims to pioneer regional cooperation in health data governance and ethical AI use.
Dzulkefly highlighted these goals at the Precision Public Health Asia 2025 Conference, attended by 500 delegates and tech exhibitors. 'Precision Public Health is no longer futuristic—it's active here and will shape a sustainable, equitable health system,' he affirmed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysiakini
6 hours ago
- Malaysiakini
Rakan KKM public or private initiative?
MP SPEAKS | Strictly, the question of whether an initiative or entity is public or private comes down to questions on ownership, control, sources of funding, distribution of profits, and purpose. Rakan KKM Sdn Bhd is 100 percent owned by the Minister of Finance Incorporated (MOF Inc). When a government-linked investment company (GLIC) investor comes in, the GLIC may take an equity stake in Rakan KKM Sdn Bhd. Ownership of Rakan KKM remains with the government, directly or through GLICs, throughout its operations. As for control, the Health Ministry is the "kementerian kawal selia" responsible for critical decisions over the management of the company. Seed funding of RM25 million from the Finance Ministry was announced in the budget. Additional scale-up funding from GLICs will be explored in Phase 2, which will be repaid through the revenues/profits of Rakan KKM operations. In all cases, sources of financing remain government or government-linked. Profit distribution is to the shareholders/owners of Rakan KKM - ie MOF Inc or GLICs. Rakan KKM's purpose As a public initiative, Rakan KKM serves five key objectives which are in the public interest: (a) In the environment of high medical price inflation, Rakan KKM provides premium economy value-based healthcare services to raise the ceiling, (b) Excess revenue from Rakan KKM will be used to cross-subsidise the services for all public patients, thus raising the floor, (c) Support the retention of ministry health workers by providing opportunities to increase their income considerably, (d) Serve as a price benchmark, including for services provided by private hospitals, to moderate medical price inflation for all, including patients who do not directly use Rakan KKM services, and (e) Provide appropriate returns for our GLIC shareholders and their members. Act 586 But why is Rakan KKM licensed under the Private Healthcare Facilities and Services Act 1998 (Act 586)? Does that make it a private initiative? The experts who drafted Act 586 had the foresight to anticipate the possibility that the government would provide health services through a corporate body. This is important to ensure a level playing field with the private sector, especially if Rakan KKM is to play a role as a price benchmark. The Act clearly states that a government corporate body should be regulated under this Act. DZULKEFLY AHMAD is Kuala Selangor MP and health minister. The views expressed here are those of the author/contributor and do not necessarily represent the views of Malaysiakini.
The Star
10 hours ago
- The Star
Asean key in affordable next-gen HIV meds
KUCHING: Asean must work together to reduce the cost of next-generation antiretroviral (ARV) drugs for HIV patients in their respective countries, says Datuk Lukanisman Awang Sauni. The Deputy Health Minister said regional cooperation was vital to procure these drugs at fair and affordable prices. 'The cost of ARV drugs is high due to their intellectual property, so we need to work together on regional procurement solutions. 'Buying in bulk through an Asean regional platform will facilitate easier access to these drugs,' he told reporters after opening the Asean regional dialogue on affordable ARV drugs and promoting community-based testing here yesterday. Lukanisman also said Malaysia was working to reduce the cost of a new fixed-dose combination drug known as Tenofovir-Lamivudine-Dolutegravir (TLD). 'The current ARV costs about RM500 a year. TLD is a new medicine, which would cost over RM200 a month but we want to reduce it to at least RM100 per month. 'The cost is higher than the previous ARV but it's more effective in treating patients,' he said.
Borneo Post
a day ago
- Borneo Post
Malaysia pushes Asean joint procurement to cut HIV treatment costs
(From left) Dr Ismuni, Lukanisman, Jamilah Anu, and Dr Veronica pose for a photo call after the opening ceremony of the Asean Regional Dialogue on Affordable ARV Drugs and Promoting CBT. – Photo by Roystein Emmor KUCHING (July 17): Deputy Health Minister Datuk Lukanisman Awang Sauni acknowledged that the high cost of antiretroviral (ARV) medication remains one of Malaysia's major challenges in HIV prevention and treatment. The government, he said, is actively pursuing regional joint procurement efforts to reduce prices. He stated that Malaysia is advocating for the use of Asean's regional cooperation platform to collectively procure ARV drugs, aiming to reduce the costs through shared procurement mechanisms. 'Malaysia is championing regional cooperation through joint procurement platforms. 'Many of these medications are tied to intellectual property protections, so a collaborative approach could help us negotiate better prices and improve access,' he told a press conference after officiating the Asean Regional Dialogue on Affordable Antiretroviral (ARV) Drugs and the Promotion of Community-Based Testing (CBT) here today. Lukanisman further revealed that the current monthly cost of the new‑generation TLD (Tenofovir, Lamivudine and Dolutegravir) regimen is approximately RM200. 'The TLD costs around RM200 per month, but we want to reduce it to at least RM100 per month. 'While the price is actually higher than the previous ARV, it is more efficient to treat patients with this TLD,' he noted. He also highlighted Malaysia's dependence on imports, primarily from India, where producers benefit from economies of scale and advanced biosimilar technology. 'We don't yet have the capacity to manufacture these high‑end ARVs domestically,' he said. In addition to treatment, Lukanisman emphasised the expansion of the national Pre‑Exposure Prophylaxis (PrEP) programme, now available at 35 Ministry of Health (MoH) clinics, including those in Kuching, Miri and Sibu. Despite early criticism, he defended PrEP as 'not just treatment, but a form of protection, especially for groups at high risk,' stressing that equal access to healthcare is a fundamental right. The ASEAN Regional Dialogue on Affordable ARV Drugs and promoting CBT is organised by the MoH, running from July 17 to 19 at the Hilton Hotel here. The dialogue is a strategic collaboration between the MoH, the state government, the Malaysian AIDS Foundation, the Malaysian AIDS Council, and regional partners from Asean member states. The three-day forum brings together policymakers, health experts, and community representatives to strengthen regional cooperation in ending AIDS by 2030, through affordable treatment and expanded community testing. Among those present were the Patron of the Malaysian AIDS Foundation Borneo Datin Patinggi Datuk Amar Jamilah Anu, Deputy Director General of Public Health Dr Ismuni Bohari, and State Director of Health Dr Veronica Lugah. ARV cost HIV Lukanisman Awang Sauni
